
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Remove Advertising filter Advertising (2)
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Complementary medicines (7) Apply Complementary medicines filter
- Fees/Payments (1) Apply Fees/Payments filter
- Remove Import/Export filter Import/Export (1)
- Remove Labelling/Packaging filter Labelling/Packaging (1)
- Legislation (3) Apply Legislation filter
- Remove Listed medicines filter Listed medicines (2)
- Manufacturing (1) Apply Manufacturing filter
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Remove Medical devices safety filter Medical devices safety (1)
- Remove Medicinal cannabis filter Medicinal cannabis (1)
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- OTC medicines (12) Apply OTC medicines filter
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Prescription medicines (6) Apply Prescription medicines filter
- Scheduling (55) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Therapeutic goods regulation (2) Apply Therapeutic goods regulation filter
- (-) Remove Medicinal cannabis filter Medicinal cannabis
- (-) Remove Import/Export filter Import/Export
- (-) Remove Listed medicines filter Listed medicines
- (-) Remove Labelling/Packaging filter Labelling/Packaging
- (-) Remove Medical devices safety filter Medical devices safety
- (-) Remove Advertising filter Advertising
Proposed changes to the Permissible Ingredients Determination: Low-negligible risk changes 2021-22
Closed on 15 September 2021
Proposed improvements to the Therapeutic Goods Advertising Code
Closed on 18 June 2021
Potential reforms to medicinal cannabis manufacturing, labelling and packaging requirement
Closed on 29 January 2021
IMDRF consultation: Proposed update to document on Post-Market Clinical Follow-Up Studies
Closed on 11 December 2020
Export of therapeutic goods from Australia
Closed on 3 February 2020
Changes to permissible ingredients - Low-negligible risk
Closed on 11 October 2019
The Scheduling Policy Framework and Advertising of Pharmacist-only medicines (Schedule 3 substances)
Closed on 28 April 2017
Labelling project 99/00 Effective by design
Closed on 23 June 2000